AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18772264 — intervention group
Group type: COMPARATOR
Intervention: Normal chest patients (control group)
Number of subjects: 20
Study 15753114 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin on alternate days
Number of subjects: 39876
Study 15753114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study 12897285 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose indomethacin (0.2 mg/kg/dose every 12 hours for 3 doses)
Number of subjects: 140
Study 12897285 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged low-dose indomethacin (0.1 mg/kg/dose daily for 6 doses)
Number of subjects: 140
Study 12897285 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose indomethacin
Number of subjects: 140
Study 12897285 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged low-dose indomethacin
Number of subjects: 140
Study 10577443 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual compression
Number of subjects: 400
Study 10577443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical clamp
Number of subjects: 400
Study 10577443 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic compression device
Number of subjects: 400
Study 7594035 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 40099
Study 7594035 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 40099
Study 7594035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-smokers
Number of subjects: 40099
Study 1851339 — intervention group
Group type: EXPERIMENTAL
Intervention: VACE regimen (vincristine 1.2 mg/m2, doxorubicin 40 mg/m2, cyclophosphamide 700 mg/m2 on day 1 plus etoposide 110 mg/m2 daily for three days)
Number of subjects: 95
Study 1851339 — intervention group
Group type: COMPARATOR
Intervention: CVACE regimen (identical to VACE for cycles 3 and 4; cycles 1, 2, 4, and 6 consisted of etoposide 110 mg/m2 for three days plus cisplatin 100 mg/m2 with mannitol diuresis on the second day)
Number of subjects: 95
Study 1851339 — intervention group
Group type: COMPARATOR
Intervention: CVACE regimen
Number of subjects: 95
Study 1851339 — intervention group
Group type: EXPERIMENTAL
Intervention: VACE regimen
Number of subjects: 95
Study 6119097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxazolam (3 mg)
Number of subjects: 73
Study 6119097 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg)
Number of subjects: 73
Study 6119097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 31550962 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (100 mg daily)
Number of subjects: 174
Study 31550962 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) plus low dose aspirin (40 mg enoxaparin and 100 mg aspirin daily)
Number of subjects: 174
Study 31550962 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) alone (40 mg enoxaparin daily)
Number of subjects: 174
Study 31550962 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 174
Study 30052964 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 965
Study 30052964 — intervention group
Group type: COMPARATOR
Intervention: Myocardial single photon emission computed tomography (SPECT)
Number of subjects: 965
Study 30052964 — intervention group
Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 965
Study 30052964 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 965
Study 28465004 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 583
Study 28465004 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 583
Study 26269685 — intervention group
Group type: EXPERIMENTAL
Intervention: OrVil™ technique
Number of subjects: 84
Study 26269685 — intervention group
Group type: COMPARATOR
Intervention: Hemi-double stapling technique (HDST)
Number of subjects: 84
Study 26269685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 84
Study 23432037 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes who reported a higher proportion of their conditions
Number of subjects: 424
Study 23432037 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing numbers of chronic conditions
Number of subjects: 424
Study 23432037 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 424
Study 22152147 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invitation to food supplementation
Number of subjects: 4436
Study 22152147 — intervention group
Group type: EXPERIMENTAL
Intervention: MMS (multiple micronutrient supplementation)
Number of subjects: 4436
Study 22152147 — intervention group
Group type: COMPARATOR
Intervention: Usual invitation to food supplementation
Number of subjects: 4436
Study 18783415 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-welded titanium frameworks
Number of subjects: 155
Study 18783415 — intervention group
Group type: COMPARATOR
Intervention: Gold alloy frameworks
Number of subjects: 155
Study 17140279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (exogenous GHB)
Number of subjects: 0
Study 15136375 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive school‐based asthma program
Number of subjects: 835
Study 11309635 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg or 120 mg)
Number of subjects: 7478
Study 11309635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7478
Study 9005911 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin for 14 days
Number of subjects: 201
Study 9005911 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin for 7 days
Number of subjects: 201
Study 8557525 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid tablets plus pyridoxin tablets once a day for 30 days
Number of subjects: 20
Study 8557525 — intervention group
Group type: COMPARATOR
Intervention: Pyridoxin only
Number of subjects: 20
Study 2796626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine, 1 mg/kg
Number of subjects: 40
Study 2796626 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 352259 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon
Number of subjects: 18
Study 352259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31638448 — intervention group
Group type: EXPERIMENTAL
Intervention: Four Conversations (online and personalized coping and decision aid curriculum)
Number of subjects: 252
Study 31638448 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed usual care conditions (control)
Number of subjects: 252
Study 31176632 — intervention group
Group type: EXPERIMENTAL
Intervention: AP‐CD/LD (50/250 mg, 50/375 mg, or 50/500 mg)
Number of subjects: 0
Study 31176632 — intervention group
Group type: EXPERIMENTAL
Intervention: AP‐CD/LD
Number of subjects: 0
Study 31176632 — intervention group
Group type: COMPARATOR
Intervention: IR‐CD/LD
Number of subjects: 0
Study 27986606 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (bolus of 0.11mg/kg, followed by a maintenance infusion of 0.12mg/kg)
Number of subjects: 28
Study 27986606 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl infusion)
Number of subjects: 28
Study 25972230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) including weight loss and physical activity
Number of subjects: 4016
Study 25972230 — intervention group
Group type: COMPARATOR
Intervention: Control group: diabetes support and education
Number of subjects: 4016
Study 24913571 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (total dose of about 40,000 U)
Number of subjects: 62
Study 22386829 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg and Amlodipine 10 mg (T/A)
Number of subjects: 706
Study 22386829 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg (A)
Number of subjects: 706
Study 19284397 — intervention group
Group type: EXPERIMENTAL
Intervention: LASER therapy
Number of subjects: 70
Study 19284397 — intervention group
Group type: COMPARATOR
Intervention: Electrotherapy (TENS, stable galvanization)
Number of subjects: 70
Study 16542638 — intervention group
Group type: EXPERIMENTAL
Intervention: High body checking (scrutinizing bodies in a critical way in the mirror)
Number of subjects: 60
Study 16542638 — intervention group
Group type: COMPARATOR
Intervention: Low body checking (refraining from body checking and examining bodies in a neutral way)
Number of subjects: 60
Study 16542638 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high and low body checking
Number of subjects: 60
Study 14996574 — intervention group
Group type: COMPARATOR
Intervention: Higher neutrophil counts (8.8 +/- 3.8) at 90 minutes for patients with closed infarct-related artery (TIMI grade 0/1 flow)
Number of subjects: 394
Study 14996574 — intervention group
Group type: COMPARATOR
Intervention: Percentage of neutrophils (73.2 +/- 10.7% for TMPG 0/1)
Number of subjects: 394
Study 14996574 — intervention group
Group type: COMPARATOR
Intervention: Neutrophil counts (8.2 +/- 3.3 for TMPG 0/1)
Number of subjects: 394
Study 14996574 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neutrophil counts
Number of subjects: 394
Study 14996574 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater percentage of neutrophils
Number of subjects: 394
Study 12052284 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 12052284 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 9066353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid/serum ratios for soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1
Number of subjects: 46
Study 9066353 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels for soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1
Number of subjects: 46
Study 9066353 — intervention group
Group type: EXPERIMENTAL
Intervention: Single periventricular gadolinium-enhancing lesion (n = 16)
Number of subjects: 46
Study 9066353 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhancing lesions detected
Number of subjects: 46
Study 8410217 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (very high doses) administered within 8 hours of injury
Number of subjects: 0
Study 8410217 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment with methylprednisolone
Number of subjects: 0
Study 8410217 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone administration
Number of subjects: 0
Study 3108851 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivanol-induced interruption of pregnancy (non-invasive)
Number of subjects: 550
Study 3108851 — intervention group
Group type: COMPARATOR
Intervention: Invasive interruption of pregnancy (control)
Number of subjects: 550
Study 31199549 — intervention group
Group type: EXPERIMENTAL
Intervention: Active BreEStim
Number of subjects: 10
Study 29474510 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite cafeteria 2.0 intervention (nudging and social marketing strategies)
Number of subjects: 30
Study 29474510 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard worksite cafeteria practices)
Number of subjects: 30
Study 26319959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pride condition
Number of subjects: 0
Study 26319959 — intervention group
Group type: EXPERIMENTAL
Intervention: Joy condition
Number of subjects: 0
Study 26319959 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 24735200 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 80
Study 24735200 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 80
Study 22500386 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinggan Huatan Huoxue Recipe (QHHR)
Number of subjects: 150
Study 22500386 — intervention group
Group type: COMPARATOR
Intervention: Danning Tablet
Number of subjects: 150
Study 20573778 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide-like diuretic (indapamide 1.5 mg SR) + ACE inhibitor (perindopril 2-4 mg)
Number of subjects: 3845
Study 20573778 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for indapamide and perindopril)
Number of subjects: 3845
Study 17646516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 2 mg
Number of subjects: 60
Study 17646516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 4 mg
Number of subjects: 60
Study 17646516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 7 mg
Number of subjects: 60
Study 17646516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 10 mg
Number of subjects: 60
Study 17646516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine 14 mg
Number of subjects: 60
Study 17136950 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily for 6 weeks
Number of subjects: 28
Study 17136950 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (un-blinded) for 3 months
Number of subjects: 28
Study 17136950 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 28
Study 11995818 — intervention group
Group type: EXPERIMENTAL
Intervention: Local implantation of bucladesine-loaded biodegradable polymeric sustained release (bcl-SR) pellets
Number of subjects: 40
Study 11995818 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy with six i.v. infusions of fotémustine
Number of subjects: 40
Study 11995818 — intervention group
Group type: COMPARATOR
Intervention: Tumor resection only
Number of subjects: 40
Study 11995818 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic fotémustine + local implantation of bcl-SR pellets
Number of subjects: 40
Study 10446490 — intervention group
Group type: EXPERIMENTAL
Intervention: KRN8602 (15 mg/m2/day for 5 days) + Cytosine arabinoside (100 mg/m2/day for 7 days)
Number of subjects: 58
Study 10446490 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin (40 mg/m2/day for 3 days) + Cytosine arabinoside (100 mg/m2/day for 7 days)
Number of subjects: 58
Study 7493059 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygent® (1.35 g PFC/kg)
Number of subjects: 30
Study 7493059 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygent® (1.8 g PFC/kg)
Number of subjects: 30
Study 2033427 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 136
Study 2033427 — intervention group
Group type: COMPARATOR
Intervention: MOPP chemotherapy
Number of subjects: 136
Study 7471802 — intervention group
Group type: EXPERIMENTAL
Intervention: Halcinonide cream (0.025%)
Number of subjects: 79
Study 7471802 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 79
Study 7471802 — intervention group
Group type: COMPARATOR
Intervention: Halcinonide cream (0.025%) and Placebo cream
Number of subjects: 79
Study 31961926 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab-based chemotherapy induction
Number of subjects: 549
Study 31961926 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-based chemotherapy induction
Number of subjects: 549
Study 31961926 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of bSUVmax
Number of subjects: 549
Study 31961926 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of bSUVmax and bSUVrange
Number of subjects: 549
Study 30862659 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted family‐model DSME (adapted DSME)
Number of subjects: 221
Study 30862659 — intervention group
Group type: COMPARATOR
Intervention: Standard DSME
Number of subjects: 221
Study 29854262 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent non-lattice fragments
Number of subjects: 32241
Study 29854262 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent lattice fragments
Number of subjects: 32241
Study 29854262 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized relational error detection methods
Number of subjects: 32241
Study 29854262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lattice vs. non-lattice fragments
Number of subjects: 32241
Study 25670836 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportal (TP) technique
Number of subjects: 70
Study 25670836 — intervention group
Group type: COMPARATOR
Intervention: Outside-in (OI) technique
Number of subjects: 70
Study 24576148 — intervention group
Group type: EXPERIMENTAL
Intervention: PSYMEPHY treatment (6-week interdisciplinary treatment)
Number of subjects: 110
Study 24576148 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard pharmacologic care)
Number of subjects: 110
Study 22860637 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 70
Study 22860637 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg AA
Number of subjects: 70
Study 22860637 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg AA
Number of subjects: 70
Study 22860637 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg AA
Number of subjects: 70
Study 19398279 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing for the Drug Free Years (PDFY)
Number of subjects: 429
Study 19398279 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 429
Study 17516992 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ(10) 100 mg, riboflavin 10 mg, niacin 50 mg along with tamoxifen 10 mg twice a day for 45 days (Group IV)
Number of subjects: 84
Study 17516992 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ(10) 100 mg, riboflavin 10 mg, niacin 50 mg along with tamoxifen 10 mg twice a day for 90 days (Group V)
Number of subjects: 84
Study 17516992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice a day for more than 1 year (Group III)
Number of subjects: 84
Study 15498622 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg/d, at least one i.v. dose)
Number of subjects: 221
Study 15498622 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone +/‐ azithromycin +/‐ metronidazole (control group)
Number of subjects: 221
Study 15498622 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 221
Study 11465936 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (500 mg b.i.d.)
Number of subjects: 289
Study 11465936 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 289
Study 9496494 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐ELS
Number of subjects: 26
Study 9496494 — intervention group
Group type: COMPARATOR
Intervention: TPN
Number of subjects: 26
Study 7990030 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental trial (lactic acidosis)
Number of subjects: 6
Study 7990030 — intervention group
Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 6
Study 2916871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg single dose)
Number of subjects: 51
Study 2916871 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (initial dose of 0.1 mg with hourly doses of 0.1 mg)
Number of subjects: 51
Study 5015049 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective vagotomy without drainage procedure
Number of subjects: 0
Study 30412905 — intervention group
Group type: COMPARATOR
Intervention: Glucose (75 g, GLU) alone
Number of subjects: 23
Study 30412905 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fat dairy milk (MILK)
Number of subjects: 23
Study 30412905 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey (WHEY)
Number of subjects: 23
Study 30412905 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein (CASEIN)
Number of subjects: 23
Study 30412905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy trials (MILK, WHEY, CASEIN)
Number of subjects: 23
Study 30412905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy milk (MILK)
Number of subjects: 23
Study 29140134 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery station access for 30 minutes post-exercise
Number of subjects: 127
Study 24725465 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with remifentanil and diclofenac (50 mg)
Number of subjects: 76
Study 24725465 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (2 mg/kg i.m.) and midazolam (7.5 mg)
Number of subjects: 76
Study 23547631 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (7 mbar) with supplemental oxygen
Number of subjects: 18
Study 23547631 — intervention group
Group type: COMPARATOR
Intervention: Supplemental oxygen only
Number of subjects: 18
Study 21061414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention consisting of twelve group-based sessions
Number of subjects: 170
Study 21061414 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 170
Study 18787094 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Replacement (FR) trial
Number of subjects: 13
Study 18787094 — intervention group
Group type: COMPARATOR
Intervention: No-Fluid Replacement (NFR) trial
Number of subjects: 13
Study 16567357 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept + DMARDs
Number of subjects: 391
Study 16567357 — intervention group
Group type: COMPARATOR
Intervention: Placebo + DMARDs
Number of subjects: 391
Study 14596626 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive (Estrostep, containing norethisterone acetate 1mg and ethinylestradiol [20, 30, 35 mg])
Number of subjects: 0
Study 14596626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11024603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (1 mg kg(‐1) bolus followed by 40 microg kg(‐1) min(‐1) for 4 hours)
Number of subjects: 6
Study 11024603 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 6
Study 8970269 — intervention group
Group type: EXPERIMENTAL
Intervention: DAB486IL-2
Number of subjects: 45
Study 8970269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1307344 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 10
Study 1307344 — intervention group
Group type: COMPARATOR
Intervention: Conventional intramuscular analgesia
Number of subjects: 10